About
BONESUPPORT AB is a Swedish biotech company based in Lund, founded in 1999. The company specializes in orthobiologics, focusing on the development and marketing of innovative injectable bioceramic bone graft substitutes. These products are designed to treat bone voids and defects resulting from trauma, infection, disease, or surgery. The flagship product line, CERAMENT®, includes a range of radiopaque, injectable, osteoconductive, and drug-eluting bioceramic materials. CERAMENT aids in bone healing by remodeling into host bone within six to twelve months. Some variants also contain antibiotics to help manage bone infections, combining regeneration with infection control. BONESUPPORT's products are primarily utilized in orthopedic surgery, aiming to enhance healing outcomes through a biodegradable scaffold that supports bone regeneration and localized drug therapy. BONESUPPORT has made significant strides since its inception, including a public listing on Nasdaq First North Growth Market in 2013 and on Nasdaq Stockholm’s main market in 2017. The company continues to focus on expanding its research, product development, and marketing efforts, particularly in the U.S. orthopedic surgery market.
Technologies
Keywords
Company Information
-
Employees 180
-
Founded 2000
-
Annual Revenue $92669000
-
Total Funding $108000000
Location
17 Scheelevaegen, Lund, Skane County, Sweden, 223 63